Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 222Observational 43Expanded_access 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Primary Myelofibrosis 3Lymphoma 3Leukemia 3Hematologic Neoplasms 3Blast Crisis 3Precancerous Conditions 2Polycythemia Vera 2Multiple Myeloma 2Mastocytosis, Systemic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Mast-Cell 2Immunologic Deficiency Syndromes 2Graft vs Host Disease 2Waldenstrom Macroglobulinemia 1Thalassemia 1Sarcoma 1Recurrence 1Preleukemia 1Pancytopenia 1Osteosclerosis 1Osteopetrosis 1Osteochondrodysplasias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1

Interventions

ruxolitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Polycythemia Vera × Myeloid × Clear all
NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Novartis

Available
Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT05269771 2025-11-05

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Novartis

No longer available
Myeloid

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡